The tumor microenvironment: shaping cancer progression and treatment response
- PMID: 38179655
- DOI: 10.1080/1120009X.2023.2300224
The tumor microenvironment: shaping cancer progression and treatment response
Abstract
The tumor microenvironment (TME) plays a crucial role in cancer progression and treatment response. It comprises a complex network of stromal cells, immune cells, extracellular matrix, and blood vessels, all of which interact with cancer cells and influence tumor behaviour. This review article provides an in-depth examination of the TME, focusing on stromal cells, blood vessels, signaling molecules, and ECM, along with commonly available therapeutic compounds that target these components. Moreover, we explore the TME as a novel strategy for discovering new anti-tumor drugs. The dynamic and adaptive nature of the TME offers opportunities for targeting specific cellular interactions and signaling pathways. We discuss emerging approaches, such as combination therapies that simultaneously target cancer cells and modulate the TME. Finally, we address the challenges and future prospects in targeting the TME. Overcoming drug resistance, improving drug delivery, and identifying new therapeutic targets within the TME are among the challenges discussed. We also highlight the potential of personalized medicine and the integration of emerging technologies, such as immunotherapy and nanotechnology, in TME-targeted therapies. This comprehensive review provides insights into the TME and its therapeutic implications. Understanding the TME's complexity and targeting its components offer promising avenues for the development of novel anti-tumor therapies and improved patient outcomes.
Keywords: Cancer associated Fibroblast; TME modulation; TME targeted therapies; angiogenesis; cytokines; eCM; immune microenvironment; immunotherapy; stromal cells.
Similar articles
-
Tumor microenvironment: recent advances in understanding and its role in modulating cancer therapies.Med Oncol. 2025 Mar 18;42(4):117. doi: 10.1007/s12032-025-02641-4. Med Oncol. 2025. PMID: 40102282 Review.
-
Taking a Full Snapshot of Cancer Biology: Deciphering the Tumor Microenvironment for Effective Cancer Therapy in the Oncology Clinic.OMICS. 2020 Apr;24(4):175-179. doi: 10.1089/omi.2020.0019. Epub 2020 Mar 13. OMICS. 2020. PMID: 32176591 Review.
-
Gynecological cancer tumor Microenvironment: Unveiling cellular complexity and therapeutic potential.Biochem Pharmacol. 2024 Nov;229:116498. doi: 10.1016/j.bcp.2024.116498. Epub 2024 Aug 17. Biochem Pharmacol. 2024. PMID: 39159874 Review.
-
Role of the tumor microenvironment in cancer therapy: unveiling new targets to overcome drug resistance.Med Oncol. 2025 May 7;42(6):202. doi: 10.1007/s12032-025-02754-w. Med Oncol. 2025. PMID: 40332723 Review.
-
Expanding horizons in cancer therapy by immunoconjugates targeting tumor microenvironments.Crit Rev Oncol Hematol. 2024 Sep;201:104437. doi: 10.1016/j.critrevonc.2024.104437. Epub 2024 Jul 6. Crit Rev Oncol Hematol. 2024. PMID: 38977144 Review.
Cited by
-
Modulation of lipid metabolism by exercise: exploring its potential as a therapeutic target in cancer endocrinology.Front Endocrinol (Lausanne). 2025 May 23;16:1580559. doi: 10.3389/fendo.2025.1580559. eCollection 2025. Front Endocrinol (Lausanne). 2025. PMID: 40487761 Free PMC article. Review.
-
Comprehensive characterization of Fidgetin on tumor immune microenvironment evaluation and immunotherapy in human hepatocellular carcinoma.Aging (Albany NY). 2024 Feb 27;16(5):4445-4468. doi: 10.18632/aging.205598. Epub 2024 Feb 27. Aging (Albany NY). 2024. PMID: 38421251 Free PMC article.
-
Tumor microenvironment and immune-related myositis: addressing muscle wasting in cancer immunotherapy.Front Immunol. 2025 May 2;16:1580108. doi: 10.3389/fimmu.2025.1580108. eCollection 2025. Front Immunol. 2025. PMID: 40386783 Free PMC article. Review.
-
Exosomal microRNAs in lung cancer: a narrative review.Transl Cancer Res. 2024 Jun 30;13(6):3090-3105. doi: 10.21037/tcr-23-2319. Epub 2024 Jun 13. Transl Cancer Res. 2024. PMID: 38988916 Free PMC article. Review.
-
Targeting MDM2-p53 interaction for breast cancer therapy.Oncol Res. 2025 Mar 19;33(4):851-861. doi: 10.32604/or.2025.058956. eCollection 2025. Oncol Res. 2025. PMID: 40191734 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical